Yoshiko Akamatsu, Senior Principal Research Scientist, AbbVie
Andrew Allen, President And Chief Executive Officer, Gritstone Oncology
Andrew Allen, M.D., Ph.D. co-founded Gritstone Oncology, Inc. and has served as our President and Chief Executive Officer and a member of our board of directors since 2015. Prior to Gritstone, in 2009, Dr. Allen co-founded Clovis Oncology, Inc., and served there as chief medical officer, and before ...
Andrew Allen, President And Chief Executive Officer, Gritstone Oncology
Julian Andreev, Fellow Scientist, Regeneron
Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc
Sameer Awsare, Associate Executive Director, The Permanente Medical Group Inc
Parastoo Azadi, Technical Director Of Analytical Services And Senior Research Scientist, Complex Carbohydrate Research Center
Julio Baez, Bioengineering Industrial Advisor, University of California San Diego
Christopher Bahl, Head Of Protein Design, Institute For Protein Innovation
Cory Brooks, Associate Professor, California State University, Fresno
Carrie Browstein, CMO, Cellectis
Samantha Bucktrout, Senior Director of Research, Parker Institute for Cancer Immunotherapy
Mr Rob Burgess, Chief Business Officer, Sino Biological Inc
Alex Burgin, Executive Director, Institute For Protein Innovation
Iain Campuzano, Principal Scientist, Amgen Inc
Ping Cao, VP, Business Development, Shanghai Henlius Biotech, Inc
Paul Carter, Senior Director And Staff Scientist, Antibody Engineering, Genentech
Brian Champion, Chief Scientific Officer, Psioxus Therapeutics Ltd
Kartik Chandran, Associate Professor, Department Of Microbiology And Immunology, Albert Einstein College of Medicine
Melody Chang, Director of Pharmacy Operations, American Oncology Network
Melody Chang, RPh, BCOP, MBA, is the Director of Pharmacy Operations of Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, with over 230 physicians, 200 nurse practitioners and physician assistants and nearly ...
Melody Chang, Director of Pharmacy Operations, American Oncology Network
Youhai Chen, Professor of Pathology and Laboratory Medicine, University of Pennsylvania School Of Medicine
Steven Corn, Founder And Chief Executive Officer, Metis Advocacy
Christina Coughlin, Chief Medical Officer, Rubius Therapeutics
Christine Coughlin joined Rubius Therapeutics as Chief Medical Officer in January 2020. She brings extensive experience leading clinical development and translational medicine teams and has a track record of building successful drug development organizations, with a particular focus in cellular...
Christina Coughlin, Chief Medical Officer, Rubius Therapeutics
Kelly Coulbourne, Allergan
James Crowe, Director, Vanderbilt Vaccine Center
Patty Culp, Senior Director of Cell Biology and Assay Development, Maverick Therapeutics
Marc Damelin, Vice President & Head of Biology, Mersana Therapeutics, Inc.
Marianne Davies, Associate Professor, Yale School Of Nursing
Jonathan Davis, Head of Innovation, Invenra INC
Brandon DeKosky, Assistant Professor Of Pharmaceutical Chemistry And Chemical Engineering, University of Kansas
lelia delamarre, Principal Scientist, Genentech
John Delaney, Director, Research Technologies And Collaborations, Amgen Inc
Liang Deng, Associate Member, Memorial Sloan-Kettering Cancer Center
Danielle Dettling, Director, Research And Development, Maverick Therapeutics
Richard Ding, Director Of Downstream Purification And Manufacturing, AnaptysBio, Inc.
Feng Dong, Senior Scientist Iii, AbbVie
Prof Stefan Duebel, Director, Braunschweig University of Technology
Colin Edgerton, Executive Chairman, American Rheumatology Network
Peter Ellmark, VP Discovery, Alligator Bioscience AB
Lauren Ely, Senior Principle Scientist, Pfizer
Yoshua Esquenazi Levy, Neurosurgeon, Memorial Hermann Texas Medical Center
Mourad Farouk Rezk, Global Head Of Medical And Regulatory, Biosimilars, Biogen
Andrea Ferrante, Principal Research Scientist, Eli Lilly and Company
Andrea Ferrante attained his M.D. at the University of Genoa (Italy) School of Medicine in 2003 and his M.B.A. in 2017 at the University of Alaska Fairbanks. His postdoctoral training includes 3 years of residency in Clinical Pathology (Italy) and 7 years of research at the Blood Research...
Andrea Ferrante, Principal Research Scientist, Eli Lilly and Company
Dana Filoti, Principal Scientist I/ Head of Research and Early Development NBE Analytical R&D, AbbVie
Tiffany Fletcher, Head of Global Biosimilar Policy & Access, Mylan
Tiffany Fletcher, Head of Global Biosimilar Policy and Access, at Mylan, is responsible for the development and support of global policies to support biosimilars and increase patient access to high quality medicine. Tiffany has over twenty years of industry experience specializing in market access...
Tiffany Fletcher, Head of Global Biosimilar Policy & Access, Mylan
John Flygare, Senior Principal Scientist, Merck And Co Inc
Alex Franzusoff, Chief Executive Officer, Pact Pharma
Agnete Fredriksen, President And Chief Scientific Officer, VACCIBODY AS
Federico Gherardini, Director, Informatics, Parker Institute for Cancer Immunotherapy
Pier Federico Gherardini is Director of Informatics at The Parker Institute for Cancer Immunotherapy. His work focuses on the integration of clinical and multi-omic data in order to support the development of clinical programs in Immuno-Oncology.Dr. Gherardini has a strong passion for the...
Federico Gherardini, Director, Informatics, Parker Institute for Cancer Immunotherapy
Raja Ghosh, Associate Professor Of Chemical Engineering And Research Chairman, McMaster University
Ms Elizabeth Hewitt Gibson, Senior Director, Operations, California Life Sciences Association - CLSA
Mr Francisco Gonzalez, Associate Principal Scientist, Fujifilm Diosynth Biotechnologies
Sangeeta Goswami, Assistant Professor, MD Anderson Cancer Center
Dr. Sangeeta Goswami is an Assistant Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Dr. Goswami obtained her Medical degree from the Gauhati Medical College in Assam, India and PhD in Immunology from...
Sangeeta Goswami, Assistant Professor, MD Anderson Cancer Center
Parag Goyal, Director Biologics R&D, Mylan Inc
Bonnie Gunn, Assistant Professor, Washington State University
Taylor Guo, Co-Founder And Chief Scientific Officer, I-Mab Biopharma
Sanjeev Gupta, General Manager - Advanced Biotech, Ipca Laboratories: Pharmaceutical Company
Jeonghoon Han, Vice President, Chief Development And Technology Officer, Eutilex Ltd
Brenda Hann, Director, Clinical Trials Operations, Stanford University School of Medicine
Brenda Hann is the Director of Clinical Research Operations in the Stanford Cancer Clinical Trials Office at Stanford Cancer Institute. The Cancer Clinical Trials Office provides central coordination and oversight of clinical staff to ensure consistent processes, regulatory compliance and improved ...
Brenda Hann, Director, Clinical Trials Operations, Stanford University School of Medicine
Matthew Harman, VP, Clinical Solutions, Employers Health
Ms Erin Harris, Chief Editor, Cell & Gene, Life Science Connect
Christopher R Heery, Chief Medical Officer, Precision BioSciences
Kristen Hege, Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol-Myers Squibb
Kevin Henry, Research Officer, National Research Council Canada
Inmaculada Hernandez, Assistant Professor (Pharmacy and Therapeutics), University of Pittsburgh
Tim Hickling, Head of Immunosafety, Roche
Lawrence Hill, Chief Executive Officer, Gan & Lee Pharmaceuticals USA
Soraya Hölper, Lab Head Mass Spectrometry, Sanofi - Biologics Research
Yue Huang, Scientist II, AstraZeneca
Li Hui, Scientific director, Biocytogen
Elizabeth Jex, Attorney Advisor, FTC
Jennifer Jung, Lab Head Mass Spectrometry, Sanofi
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
Balveen Kaur, Professor And Vice Chair Research, The University of Texas Health Science Center at Houston
Rahul Kaushik, Vice President and Head of Antibody/Protein Process Development and Manufacturing, FibroGen Inc
Dr Hans S Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc.
Bruce Keyt, CSO, IgM. Biosciences Inc
Payal Khandelwal, Head of Product Management, Protein Analysis, Sartorius
Philip Kim, Associate Professor, University of Toronto
Kyung-Ah Kim, Vice President, Samsung Bioepis
Leonid Kirkovsky, Director, Pfizer
Vadim Klyushnichenko, Vice President Of Pharmaceutical Development And Quality, Calibr, a division of Scripps Research
Vadim Klyushnichenko, Ph.D. has served as Vice President of Pharmaceutical Development and Quality at Calibr, a division of The Scripps Research Institute since April 2016. He is responsible for process development, GMP manufacturing, quality assurance, CMO/CRO management, and the supply chain of...
Vadim Klyushnichenko, Vice President Of Pharmaceutical Development And Quality, Calibr, a division of Scripps Research
Kevin Knopf, Chairman Hematology And Oncology, Highland Hospital
Karin Koch, University Lab Partners
David Korn, Vice President, Intellectual Property and Law, phrma
Giedre Krenciute, Assistant Member, St. Jude Children's Research Hospital
Dr. Rajesh Krishnan, Chief Technology Officer, Oncternal Therapeutics
Stanley Krystek, Research Fellow, Bristol-Myers Squibb
Daniel Lafkas, Scientist, Genentech
Jonathan Lai, Professor of Biochemistry, Albert Einstein College of Medicine
Hun Lee, Global Leader of Protein Design, Synbio Technologies
Dr James Legg, Vice President, Research And Development, Crescendo Biologics Ltd
Steve Lehrer, Managing Director, SBLehrer LLC
Bruce Leicher, Strategic Legal Advisor and Adjunct Professor in Biotechnology Law, University of New Hampshire
Hy Levitsky, President of Research & Development, Century Therapeutics
Nathan Lewis, Associate Professor, Department Of Pediatrics And Bioengineering,, University of California San Diego
Ming Li, Assistant Professor, Memorial Sloan-Kettering Cancer Center
Tony Liu, CEO & CFO, Cellular Biomedicine Group, Inc
David Liu, Instructor In Medicine, Dana Farber Cancer Institute
Cate Lockhart, Executive Director, Biologics and Biosimilars Collective Intelligence Consortium
Lawrence Lum, Professor Of Oncology, University Of Virginia
Geoffrey Lynn, Chief Executive Officer and Co-Founder, Avidea Technologies
Dr. Geoffrey Lynn is CEO and Co-founder of Avidea Technologies (Baltimore, MD). In this capacity, Dr. Lynn is leveraging his background in synthetic chemistry and cellular immunology to lead Avidea’s efforts to develop immunotherapies for cancer treatment that are enabled by innovations around two...
Geoffrey Lynn, Chief Executive Officer and Co-Founder, Avidea Technologies
Maria-Céu Machado, Vice President, Federation of European Academies of Medicine
Julie Marechal-Jamil, Biosimilars Policy & Science, Medicines for Europe
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Pierre Martineau, Team leader, IRCM & Scientific Advisor, Mabqi
Marc Martinez-Llordella, Founder, Vice President Biology, Quell Therapeutics
Ivan Mascanfroni, Director of Immunology, Pandion Therapeutics
Ali McBride, Clinical Coordinator, University Of Arizona
Werner Meier, Chief Scientific Officer, Revitope Oncology, Inc.
Ira Mellman, Vice President, Cancer Immunology, Genentech
Jeffrey Miller, Deputy Director, University of Minnesota
John Misasi, Staff Clinician, NIH
Si Mou, Scientist I, AstraZeneca
Liviu Movileanu, Professor, Department Of Physics, Syracuse University
Ruipeng Mu, Senior Scientist, AstraZeneca
Patricia Odermatt, Single B cell Scientist, Genovac
Ted Okon, Executive Director, Community Oncology Alliance
Sofia Oliveira Martins, Professor, University of Lisbon
Sonia Oskouei, VP, Biosimilars, Cardinal Health
Kathy Oubre, COO, Pontchartrain Cancer Center
Kathy Oubre is the Chief Operating Officer for Pontchartrain Cancer Center with 2 sites in southeast Louisiana. She is the President of Louisiana Medical Group Managers Association and immediate past president of the Coalition of Hematology and Oncology Practices. Kathy is also a Board member of...
Kathy Oubre, COO, Pontchartrain Cancer Center
Rachel Overman, JPM CBRN Medical
Mr Lauri Peil, Key Account And Technology Officer, Icosagen Cell Factory OU
Samanthi Perera, Associate Principal Scientist, Quantitative Biosciences, Merck
Edith Perez, Chief Medical Officer, Bolt Biotherapeutics
Joann Peters, VP Clinical & Business Operations, Geneos Therapeutics
Elizabeth Pham, Scientist, Oncology, Amgen
Dr Laurent Poirot, SVP Immunology, Cellectis SA
Ned Pojskic, Leader, Pharmacy And Health Provider Relations, Greenshield Insurance Brokers LLC
Mr Robert Popovian, Vice President Of Government Relations, Pfizer
David L Porter, Director, Cell Therapy And Transplantation, University of Pennsylvania
Matthew Porteus, Associate Director, Definitive And Curative Medicine, stanford university
Mark Poznansky, Director, Vaccine And Immunotherapy Center, Massachusetts General Hospital
Mark C. Poznansky MD, PhD is an Associate Professor of Medicine at Harvard Medical School and Attending Physician in Infectious Diseases Medicine at the Massachusetts General Hospital. Dr. Poznansky runs a laboratory funded by the NIH, Juvenile Diabetes Research Foundation, The Marsha Rivkin Center ...
Mark Poznansky, Director, Vaccine And Immunotherapy Center, Massachusetts General Hospital
Nina Prak, Professor of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania
James Purcell, Program Director, Oncology Discovery, AbbVie
Ellen Pure, Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine
Kamal Puri, CSO, Oncoresponse, Inc.
Yu Qiu, Principal scientist, Sanofi
David Quach, Instructor, Baylor College of Medicine
Maryam Raeeszadeh-Sarmazdeh, Assistant Professor of Chemical Engineering, University of Nevada
Jack A Ragheb, Senior Medical Fellow Of Immunology, Eli Lilly and Company
Eva Rahman Kabir, Professor, Brac University
Sundar Ramanan, Vice President, Head, Global Regulatory Affairs, Biocon Pharmaceuticals
Dr Vasu Rangadass, President & CEO, L7 Informatics
Romesh Rao, Research Associate, Seattle Genetics Inc
David Raulet, Lab Head, Faculty Director, Immunotherapeutics and Vaccine Research Initiative, UC Berkeley
Janice Reichert, Executive Director, The Antibody Society
Anton Rosenbaum, Head of Regulated Bioanalysis and OMICS by LC-MS, AstraZeneca
Dr Rafael Rosengarten, CEO, Genialis, Inc
Theodore Roth, Managing Director And Phd Student, University of California, San Francisco
Brandon Ruotolo, Professor Of Chemistry, University of Michigan
Jack Sadowsky, Scientist, Genentech
Yardena Samuels, Professor, Weizmann Institute
Erica Ollmann Saphire, Professor, La Jolla Institute for Allergy and Immunology
Will Singleterry, Commercial Director – Immuno-Oncology, LUMICKS
Jeffrey Skolnik, Senior Vice President Of Clinical Development, Inovio Pharmaceuticals
Alan Smith, Executive Vice President, Technical Operations, Bellicum Pharmaceuticals
Mariana Socal, Assistant Scientist, Johns Hopkins University
Peggy Sotiropoulou, Head of R&D, Celyad Oncology
Jamie Spangler, Assistant Professor, John Hopkins University
Matthew Spear, Chief Medical Officer, Poseida Therapeutics, Inc.
Ryan Stafford, Sr Director, Antibody Engineering, Immune-Onc Therapeutics
Gary Starling, Associate Vice President, Discovery Biologics, Merck
Graham Statt, Assistant Deputy Minister Of Alberta Health, Pharmaceutical And Supplementary Benefits And Vice Chair, The pan-Canadian Pharmaceutical Alliance
Blaine Stine, Director, Global Biologics Discovery, AbbVie
Mr Pawel Stocki, Reseach Director, Ossianix, Inc.
Mr Lars Stockl, Senior Director Buisness Development, FyoniBio – Service Branch of Glycotope
Sebastian Stolzenberg, Postdoctoral Project Leader, Freie University of Berlin
Anish Suri, Chief Scientific Officer, Cue Biopharma
Sean Taylor, Field Application Scientist Manager, North America, GenScript
Eva Temkin, Acting Director for Policy, Office of Therapeutic Biologics and Biosimilars, FDA
Eva Temkin is the Acting Director for Policy in the Office of Therapeutics and Biologics within FDA’s Center for Drug Evaluation and Research. In this role, she oversees the development and implementation of regulatory policy related to biosimilar, interchangeable, and therapeutic biologic...
Eva Temkin, Acting Director for Policy, Office of Therapeutic Biologics and Biosimilars, FDA
Paul Thomas, Chief Commercial Officer, US; Biocon Biologics, Biocon Biologics